舒利迭吸入剂治疗稳定期中、重度慢性阻塞性肺疾病患者临床研究

Clinical study of Seretide in treatment of moderate-evere chronic obstructive pulmonary diseases

目的研究舒利迭(沙美特罗/丙酸氟替卡松粉吸入剂)对稳定期中、重度慢性阻塞性肺病患者肺功能和生活质量的影响。方法将60例稳定期中、重度COPD患者随机分为两组,两组基础治疗相同,实验组在基础治疗上加用舒利迭吸入(50μg/250μg,1吸/次,2次/d)。于入组时、用药后12周行肺功能检查,同时观察用药后对患者临床症状及体征的改善情况,采用圣·乔治(St·George)呼吸疾病问卷(SGRQ)的方法进行客观评分,从而对患者生活质量进行评价。结果两组肺功能均有改善,实验组肺功能和临床症状积分的改善程度远高于对照组。结论吸入舒利迭能显著改善中重度COPD患者的肺功能和生活质量。

【Objective】To evaluate the effect of inhaled Seretide（salmeterol-fluticasone propionate） in the treatment of moderate/severe chronic obstructive pulmonary diseases（COPD）.【Methods】The sixty patients with moderate/severe COPD were randomly divided into two groups, the control group and the experimental group. T Baseline treatments were similar in all patients Additionally, the patients in experimental group were treated with inhaled seretide, wice daily 50/ 250μg dosage.Lung function was examined at the time of hospitalizing and 12 weeks after therapy. According to the methods of standard grade of respiratory diseases questionnaire（SGRQ） introduced by St. George, the clinical symptom questionnaire and physical sign survey were graded.【Results】lung function of two groups respectively improved, however, in the experimental group, the degree of lung function and clinical symptom standard grades was higher than that of the control group.【Conclusion】Inhaled Seretide could significantly improve the lung function and life standards of patients with moderate-severe COPD.